Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 13/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18685298 | 1.00 | CCR2 (0.48) | CCR2PTGS2HSD11B1MEN1KMT2A | |
| SCHEMBL6130274 | 0.86 | CCR2 (0.44) | CCR2PTGS2HSD11B1MEN1KMT2A | |
| SCHEMBL6130273 | 0.86 | CCR2 (0.44) | CCR2PTGS2HSD11B1MEN1KMT2A | |
| SCHEMBL6130312 | 0.86 | CCR2 (0.44) | CCR2PTGS2HSD11B1MEN1KMT2A | |
| SCHEMBL29221489 | 0.84 | CCR2 (0.46) | CCR2HSD11B1MEN1KMT2AMAOB | |
| SCHEMBL23375795 | 0.83 | LMNA (0.49) | CCR2HSD11B1MEN1KMT2AMAOB | |
| SCHEMBL23375794 | 0.83 | LMNA (0.49) | CCR2HSD11B1MEN1KMT2AMAOB | |
| SCHEMBL21447252 | 0.83 | LMNA (0.49) | CCR2HSD11B1MEN1KMT2AMAOB | |
| SCHEMBL23356985 | 0.83 | LMNA (0.49) | CCR2HSD11B1MEN1KMT2AMAOB | |
| SCHEMBL21447253 | 0.83 | LMNA (0.49) | CCR2HSD11B1MEN1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9914702-B2 | Amine derivatives as potassium channel blockers | BIONOMICS LIMITED (AU) | 2018-03-13 | — | — | US | disclosed |
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | BIONOMICS, LTD (AU) | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088519-A1 | AMINE DERIVATIVES AS POTASSIUM CHANNEL BLOCKERS | KCNA3, KCNH3, KCNK3 | CCR2 708/4885PTGS2 2560/4885HSD11B1 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.